Malignancies clinical trials at UCLA
2 in progress, 1 open to eligible people
Extension Study for Patients Previously Enrolled in Studies With Pelabresib
open to eligible people ages 18 years and up
The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants who discontinued pelabresib (for any other reason than participating in this extension study), may be enrolled in this extension study to evaluate the survival and leukemia-free survival (for patients with hematological malignancies) or only the Survival Follow-up (for all the other patients).
Los Angeles, California and other locations
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Sorry, in progress, not accepting new patients
This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.
Los Angeles, California and other locations
Our lead scientists for Malignancies research studies include Gary J. Schiller, MD Deborah J. Wong, MD, PhD.
Last updated: